McGregor BA, McKay RR, Braun DA, et al. - In this multicenter phase, II trial, individuals underwent baseline biopsy and received atezolizumab 1,200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks, in order to assess atezolizumab linked with bevacizumab in individuals with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ≥ 20% sarcomatoid differentiation. A total of 60 individuals took at least 1 dose of either study agent, the majority were treatment naïve. It was found that in people with variant histology RCC or RCC with ≥ 20% sarcomatoid differentiation, atezolizumab and bevacizumab were safe and led to objective responses.